All In Biotech

Drug Trial Radar · NCT05568095

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,040 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,040

Actual

Start

Nov 21, 2022

Primary completion

Aug 28, 2026

Study completion Aug 28, 2026

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences; Taiho Pharmaceutical Co., Ltd.
First posted
Oct 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Conditions

  • Advanced Upper Gastrointestinal Tract Adenocarcinoma

Interventions

  • DomvanalimabDrug

    Intravenous (IV) Aqueous Solution

  • ZimberelimabDrug

    IV Aqueous Solution

  • CapecitabineDrug

    Oral Tablets

  • FluorouracilDrug

    IV Aqueous Solution

  • LeucovorinDrug

    IV Aqueous Solution

  • OxaliplatinDrug

    IV Aqueous Solution

  • NivolumabDrug

    IV Aqueous Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From date of randomization until date of death from any cause (Approximately 15 months)]

Locations

168 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    Santa Monica, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Fort Myers, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    Louisville, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Saint Louis Park, Minnesota

  • Research Site

    Mineola, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Mayfield Heights, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Nashville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    La Rioja, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Clayton, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Barretos, Brazil

  • Research Site

    Ijuí, Brazil

  • Research Site

    Natal, Brazil

  • Research Site

    Porto Alegre, Brazil

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.